Specify a stock or a cryptocurrency in the search bar to get a summary
Theranexus SA
ALTHXTheranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France. Address: 60, Avenue Rockefeller, Lyon, France, 69008
Analytics
WallStreet Target Price
3.71 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALTHX
Dividend Analytics ALTHX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALTHX
Stock Valuation ALTHX
Financials ALTHX
Results | 2019 | Dynamics |